You can trust that this will be a subject for CSAP’s virtual lobby day on April 21.
Still working on some potential dates for a meeting between the California Pharmacists Association and CSAP.
Paul Yoder of SYASL will testify again on this issue at the Board of Pharmacy next week.
In an interesting twist this week, the Board of Pharmacy issued the following message to pharmacists and other interested parties (emphasis added):
“The Board of Pharmacy is aware of two recent court rulings, one of which seeks to remove the FDA approval of mifepristone. The ruling issued by Federal Judge Matthew Kacsmaryk, District Court for the Northern District of Texas, included a preliminary injunction in the case ordering a hold on the FDA’s approval of mifepristone. The ruling also included a stay of the ruling through April 14, 2023 to allow an opportunity for an appeal to be filed.
A second ruling from Federal Judge Thomas O. Rice, District Court for Eastern District of Washington, orders the FDA to maintain the current FDA approval of mifespristone, though the federal government has sought clarification of the reach of that ruling.
The Board is releasing this information to assure licensees that mifepristone remains an FDA-approved drug that is legal to dispense pursuant to a valid prescription under both federal and California law. The Board reminds licensees of requirements included inBusiness and Professions Code section 733, including provisions that establish, as unprofessional conduct, a licensee obstructing a patient in obtaining a prescription drug or device ordered for that patient as specified. The Board will continue to monitor this issue and will release updated information when available.”
